Nuclear receptor coactivator 3

Tumor Marker May Help Overcome Endocrine Treatment-Resistant Breast Cancer

Retrieved on: 
Thursday, May 20, 2021
Medicine, Clinical medicine, Branches of biology, La Jolla, San Diego, Sanford Burnham Prebys Medical Discovery Institute, Stem cell research, Breast cancer, Cancer, HER2/neu, Breast cancer management, Nuclear receptor coactivator 3

b'LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy.

Key Points: 
  • b'LA JOLLA, Calif., May 19, 2021 /PRNewswire/ -- A study led by scientists at Sanford Burnham Prebys Medical Discovery Institute has identified a tumor marker that may be used to predict which breast cancer patients will experience resistance to endocrine therapy.
  • For decades, these tumors have been treated with anti-estrogen (endocrine) therapies to lower estrogen levels and help slow the cancer\'s growth.
  • "Unfortunately, this unleashes the detrimental effects of HER2, and patients become resistant to endocrine therapy--resulting in relapse, metastasis and death.
  • "\nThe National Cancer Institute (NCI) estimates that 281,550 women in the U.S. will be diagnosed with breast cancer in 2021, and 43,600 women will eventually die from the disease.